Publications by authors named "Kenneth P Johnson"

Claim this Profile
G
Global Retinoblastoma Presentation and Analysis by National Income Level.

JAMA Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microperimetry and swept-source optical coherence tomography in the assessment of the preferred retinal locus in a child with macular retinoblastoma in the remaining eye.
Kenneth P Johnson, Aisha McLean, Gary S Rubin, Vasilios P Papastefanou, Aadil Hussain

J AAPOS· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focal laser treatment in addition to chemotherapy for retinoblastoma.
Ido D Fabian, Kenneth P Johnson, Andrew W Stacey, Mandeep S Sagoo, M A Reddy

Cochrane Database Syst Rev· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis.
Ido D Fabian, Andrew W Stacey, Kenneth P Johnson, Zerrin Onadim, Tanzina Chowdhury

Br J Ophthalmol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Kenneth P Johnson

Expert Rev Neurother· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of a multiple sclerosis relapse: the patient's perspective.
Merrikay Oleen-Burkey, Jane Castelli-Haley, Maureen J Lage, Kenneth P Johnson

Patient· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.
Kenneth P Johnson

Expert Opin Drug Metab Toxicol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Kenneth P Johnson

Ther Clin Risk Manag· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeing injectable ms therapies differently: they are more similar than different.
Kenneth P Johnson, Robert J Fox, Douglas L Arnold

Neurology· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Kenneth P Johnson, Deborah L Due

Expert Rev Pharmacoecon Outcomes Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Jane Castelli-Haley, MerriKay A Oleen-Burkey, Maureen J Lage, Kenneth P Johnson

Adv Ther· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Jane Castelli-Haley, MerriKay Oleen-Burkey, Maureen J Lage, Kenneth P Johnson

Adv Ther· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Kenneth P Johnson

Neurologist· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapses matter: the costs & consequences of multiple sclerosis relapses.
Patricia K Coyle, Kenneth P Johnson

J Neurol Sci· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control of multiple sclerosis relapses with immunomodulating agents.
Kenneth P Johnson

J Neurol Sci· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Steven R Schwid, Andrew D Goodman, Amy Weinstein, Michael P McDermott, Kenneth P Johnson

J Neurol Sci· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
Filippo Martinelli Boneschi, Marco Rovaris, Kenneth P Johnson, Aaron Miller, Jerry S Wolinsky

Mult Scler· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.
Suhayl Dhib-Jalbut, Man Chen, Areen Said, Min Zhan, Kenneth P Johnson

J Neuroimmunol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical issues in the management of multiple sclerosis. Introduction.
Kenneth P Johnson, Lance D Blumhardt

Neurology· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis